Wall Street analysts predict that Agile Therapeutics, Inc. (NASDAQ:AGRX) will report earnings per share of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.21). Agile Therapeutics posted earnings per share of ($0.27) in the same quarter last year, which would suggest a positive year-over-year growth rate of 7.4%. The firm is scheduled to report its next earnings report on Monday, November 6th.

According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.06) to ($0.98). For the next financial year, analysts expect that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($1.28) to ($0.09). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same period last year, the firm earned ($0.29) earnings per share.

Several analysts have recently commented on AGRX shares. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. ValuEngine lowered shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Royal Bank Of Canada increased their price target on shares of Agile Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday. Janney Montgomery Scott reaffirmed a “buy” rating and set a $13.00 price target on shares of Agile Therapeutics in a research note on Thursday, September 7th. Finally, HC Wainwright started coverage on shares of Agile Therapeutics in a research note on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $9.08.

Shares of Agile Therapeutics (NASDAQ AGRX) opened at 3.83 on Friday. The firm’s market capitalization is $110.33 million. The company has a 50-day moving average price of $3.56 and a 200 day moving average price of $3.45. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.95.

ILLEGAL ACTIVITY WARNING: “Agile Therapeutics, Inc. (AGRX) Expected to Post Earnings of -$0.25 Per Share” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/16/agile-therapeutics-inc-agrx-expected-to-post-earnings-of-0-25-per-share.html.

In related news, Chairman Alfred Altomari purchased 10,000 shares of the company’s stock in a transaction on Friday, August 25th. The shares were bought at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the transaction, the chairman now owns 161,587 shares of the company’s stock, valued at $539,700.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGRX. Royce & Associates LP increased its position in shares of Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock worth $3,745,000 after acquiring an additional 11,000 shares in the last quarter. Royal Bank of Canada grew its position in Agile Therapeutics by 608.0% during the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in Agile Therapeutics during the second quarter valued at approximately $122,000. Susquehanna International Group LLP purchased a new position in Agile Therapeutics during the second quarter valued at approximately $205,000. Finally, LMR Partners LLP purchased a new position in Agile Therapeutics during the second quarter valued at approximately $211,000. Institutional investors and hedge funds own 67.59% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.